Cleared Traditional

TDX COCAINE METABOLITE (K854163) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K854163 · Abbott Laboratories · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1985
Decision
21d
Days
Class 2
Risk

K854163 is an FDA 510(k) clearance for the TDX COCAINE METABOLITE. Classified as Enzyme Immunoassay, Cocaine And Cocaine Metabolites (product code DIO), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on November 5, 1985 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3250 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Laboratories devices

Submission Details

510(k) Number K854163 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 15, 1985
Decision Date November 05, 1985
Days to Decision 21 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 88d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites

All 46
Devices cleared under the same product code (DIO) and FDA review panel - the closest regulatory comparables to K854163.
LABELING CHANGE COAT-A-COUNT COCAINE METABOLITE
K873751 · Diagnostic Products Corp. · Oct 1987
LABELING CHANGE COCAINE METABOLITE DOUBLE ANTIBODY
K873752 · Diagnostic Products Corp. · Oct 1987
COCAINE METABOLITE ROCHE(R) EIA
K863843 · Roche Diagnostic Systems, Inc. · Mar 1987
EMIT D.A.U. COCAINE ASSAY
K843556 · Syva Co. · Oct 1984
EMIT 700 COCAINE METABOLITE ASSAY
K843160 · Syva Co. · Aug 1984
EMIT ST. URINE COCAINE METABOLITE
K834549 · Syva Co. · Mar 1984